Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. April 2017 08:30 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar’s Radiotherapeutic PDCs Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical Studies

MADISON, Wis., April 27, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces preclinical...
25. April 2017 08:30 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar Biosciences Receives Additional U.S. Patents for PDC Optical Agents in the Detection of Multiple Cancers

MADISON, Wis., April 25, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces the United...
21. April 2017 16:15 ET | Quelle: Cellectar Biosciences, Inc.

UPDATED: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer

MADISON, Wis., April 21, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed John Friend,...
18. April 2017 08:30 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar Biosciences Receives Japanese Patent for CLR 131 and CLR 125 for the Treatment of Cancer Stem Cells

MADISON, Wis., April 18, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces the Japanese...
12. April 2017 08:30 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer

MADISON, Wis., April 12, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed John Friend,...
10. April 2017 16:05 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar Biosciences Adds Industry Veterans Douglas Swirsky and Frederick Driscoll to Its Board of Directors

MADISON, Wis., April 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed Douglas J....
30. März 2017 08:30 ET | Quelle: Cellectar Biosciences, Inc.

After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers

MADISON, Wis., March 30, 2017 (GLOBE NEWSWIRE) -- Madison, Wis. Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces the initiation of...
21. März 2017 08:30 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar Biosciences Further Deepens Intellectual Property Portfolio with Patent Grant for PET Imaging PDC

MADISON, Wis., March 21, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces the United...
15. März 2017 16:15 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar Biosciences Reports 2016 Company Performance and Continued Progress in First Quarter 2017

MADISON, Wis., March 15, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces financial...
14. März 2017 08:30 ET | Quelle: Cellectar Biosciences, Inc.

Newly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences’ Intellectual Property Portfolio

MADISON, Wis., March 14, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces the Japanese...

Vorherige Seite